Oxford Bio abandons prostate cancer vaccine study
LONDON (Reuters) – Britain’s Oxford BioMedica said on Wednesday it was closing a mid-stage clinical trial of its cancer vaccine TroVax in U. S. patients with prostate cancer, dealing a further blow to the troubled product. Shares in the company fell more than 9 percent on the news. The group had been testing TroVax in men with progressive hormone refractory prostate cancer but it faced an uphill struggle, given the arrival of new products for the disease and other clinical trials targeting the same indication. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply